We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Continued Early Intervention for Recent-onset Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00184509
Recruitment Status : Terminated
First Posted : September 16, 2005
Last Update Posted : January 26, 2017
Sponsor:
Collaborator:
The Research Council of Norway
Information provided by:
Norwegian University of Science and Technology

Brief Summary:
The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.

Condition or disease Intervention/treatment Phase
Schizophrenia Behavioral: integrated psychosocial treatment (behavior) Phase 3

Detailed Description:

Early intervention for schizophrenia has spawned considerable enthusiasm among clinicians without solid research evidence to suport its benefits and costs. The present study is a random-controlled study of integrated biomedical and psychosocial treatment on a population of recent-onset cases.

Comparison(s): 50 consecutive referrals with schizophrenic disorders of less than two years duration were allocated randomly to a comprehensive model of integrated treatment or standard care for two years. Main outcome measures was psychopathology, psychosocial functioning and hospital admissions.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.
Study Start Date : February 1993
Estimated Study Completion Date : May 1998

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources




Primary Outcome Measures :
  1. Rehospitalizations and psychotic relapse at two years

Secondary Outcome Measures :
  1. Psychopathology, psychosocial changes, functioning, antipsychotic medication


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • first-episode schizophrenia

Exclusion Criteria:

  • acute psychosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184509


Locations
Norway
Norwegian University of Science and Technology
Trondheim, Norway, N-7000
Sponsors and Collaborators
Norwegian University of Science and Technology
The Research Council of Norway
Investigators
Study Director: K. Gunnar Gøtestam, MD Norwegian University of Science and Technology